Stock index futures rose on Friday, a day after Wall Street’s sell-off, while investors digested Amazon’s earnings results.

Pfizer reported positive Phase 2b topline results for its GLP-1 candidate in adults with obesity or overweight without type 2 diabetes. ・The company plans to launch more than 20 trials in 2026, ...

One of the latest voices weighing in is Jason Gerberry of Bank of America, who reiterated a Hold (Neutral) stance on Pfizer on February 4, 2026, setting a price objective of $27.00. This target sits ...

Pfizer reported strong mid-stage weight loss trial results for its monthly obesity drug and posted fourth-quarter earnings ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and J&J (NYSE: JNJ) primarily due to ...

PayPal ( PYPL) stock tumbled 16.9% before the opening bell after the fintech issued disappointing guidance, delivered weaker-than-expected Q4 earnings and revenue, and replaced its CEO. The board ...

Pfizer 2025 earnings. That's the good news. The bad news is that while Pfizer "beat" on both sales and adjusted earnings, its ...

Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of −11% of its value over that period. This sustained sell-off has wiped ...

Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor ...

Pfizer has beaten its earnings per share (EPS) estimates in its past 12 quarters. Beating EPS estimates hasn't always meant positive movements for Pfizer's share price. The stock's low valuation and ...

According to TipRanks.com, Williams is a 2-star analyst with an average return of 1.6% and a 41.2% success rate. Williams covers the Healthcare sector, focusing on stocks such as Alterity Therapeutics ...